Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Novel classes of antibiotics that are useful against resistant bacteria are a major need in human medicine. Cationic antimicrobial peptides are utilised as nature's antibiotics, being produced constitutively or in response to infection in virtually every type of organism from plants and insects to man. Thus, these peptides are now being considered as potential antibiotics for infections. They have the following assets: structural diversity, rapid bactericidal action, a broad spectrum of activity that includes most of the clinically important resistant pathogens, and several ancillary activities which can include antifungal, antiviral, anti-endotoxin activities, and promotion of wound healing. Cationic peptides and proteins are now proceeding through clinical trials as topical antibiotics and anti-endotoxins.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1517/13543784.7.2.167 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!